Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier, will be honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference, the premier U.S. sexual wellness industry event. The award will be presented today, August 5, 2025, during the conference held in Nashville, Tennessee.
The STIMULATE Conference is North America’s only trade show and leadership summit focused exclusively on sexual wellness, innovation, and empowerment. This year, Saundra Pelletier will be recognized alongside an elite group of female founders who are redefining what it means to lead in spaces historically overlooked — especially when it comes to reproductive health, autonomy, and the language we use to discuss them.
This honor is especially meaningful as it falls during Say Vagina Month— a bold public initiative launched by Evofem to end the shame and censorship surrounding vaginal health and advocate for medically accurate, empowering language in healthcare and social discourse.
“When we talk about birth control, the message is almost always fear-based,” said Saundra Pelletier. “But let’s be honest: if we’re using birth control, it’s because of sex. So, let’s talk about sex. Let’s talk about satisfaction. Let’s talk about pleasure. Because women deserve more than prevention — they deserve agency, honesty, and joy in the conversation. That’s what this award means to me.”
Evofem engages healthcare providers on the importance of addressing sexual satisfaction as part of their contraceptive counseling, leveraging compelling data published in the Journal of Sexual Medicine. The data demonstrate that nearly 90% of women using Evofem’s hormone-free contraceptive, PHEXXI® (lactic acid, citric acid, and potassium bitartrate), improved or maintained their level of sexual satisfaction in the Phase 3 AMPOWER trial.
As a company led by women and committed to empowering women through science, advocacy, and access, Evofem views this recognition as not just an award — but a call to keep pushing forward.
Read Also: Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
